Categories Cannabis, Earnings Call Transcripts

Canopy Growth Corporation (CGC) Q4 2021 Earnings Call Transcript

CGC Earnings Call - Final Transcript

Canopy Growth Corporation (NASDA: CGC) Q4 2021 earnings call dated June 01, 2021

Company Participants:

Judy Hong — Vice President, Investor Relations and Competitive Intelligence

David Klein — Chief Executive Officer

Mike Lee — Executive Vice President and Chief Financial Officer

Analysts:

Heather Balsky — Bank of America Securities — Analyst

Adam Buckman — Scotiabank — Analyst

Vivien Azer — Cowen and Company — Analyst

Graeme Kreindler — Eight Capital — Analyst

Rupesh Parikh — Oppenheimer & Co. — Analyst

Michael Lavery — Piper Sandler — Analyst

Aaron Grey — Alliance Global Partners — Analyst

Glenn Mattson — Ladenburg Thalmann & Co. — Analyst

John Chu — Desjardins Capital — Analyst

Pablo Zuanic — Cantor Fitzgerald — Analyst

Presentation:

Operator

Good morning. My name is Mariama, and I will be your conference operator today. I would like to welcome you to Canopy Growth Fourth Quarter and Fiscal Year 2021 Financial Results Conference Call. [Operator Instructions]

I will now turn the call over to Judy Hong, Vice President, Investor Relations. Judy, you may begin the conference.

Judy Hong — Vice President, Investor Relations and Competitive Intelligence

Thank you, Mariama, and good morning, everyone. Thank you all for joining us today. On our call today, we have Canopy’s CEO, David Klein, and our CFO, Mike Lee.

Before financial markets opened today, Canopy issued a press release announcing our financial results for fourth quarter and fiscal year ended March 31, 2021. This news release is available on our website under the investors tab, and will be filed on our EDGAR and SEDAR profiles. We have also posted our supplemental earnings presentation on our website.

Before we begin, I would like to remind you that our discussion during this call will include forward-looking statements that are based on management’s current views and assumptions and that this discussion is qualified in its entirety by the cautionary note regarding forward-looking statements included at the end of this morning’s news release. Please review today’s earnings release and Canopy’s reports filed with the SEC and SEDAR for various factors that could cause actual results to differ materially from projections.

In addition, reconciliations between any non-GAAP measures to their closest reported GAAP measures are included in our earnings release. Please note that all financial information is provided in Canadian dollars unless otherwise noted.

Following prepared remarks by David and Mike, we will conduct a question-and-answer session. To ensure that we get to questions from as many analysts as possible, we ask analysts to limit themselves to one question.

With that, I’ll turn the call over to David. David, please go ahead.

David Klein — Chief Executive Officer

Thank you, Judy, and good morning, everyone.

I’d like to begin today’s call reflecting on our past fiscal year, including our fourth quarter performance. Then I’ll provide some thoughts on the continued progress Canopy is making against our business transformation, and share with you why we are confident about how Canopy is positioned to lead this dynamic industry. Mike will then discuss our quarterly and annual performance in more detail and offer some perspectives on our outlook.

However, before we get underway this morning it’s important we take a moment to reflect on the news coming out of Canada this past week. An indigenous community uncovered the remains of 215 children on the grounds of a former residential school in Kamloops, British Columbia. This discovery is a sobering reminder of the atrocities indigenous communities were subjected to in Canada with thousands of children removed from their families, sent to schools, never to return again for their communities. Our thoughts are with those who are affected by this tragic discovery.

Turning to the business at hand, fiscal ’21 was a year of transition for Canopy. Over the course of the year, significant work was done to rightsize and rewire the organization. Through a series of strategic actions, we’ve built a more efficient and focused organization. Our full year results showcase the tremendous progress we’ve made as we not only had to contend with our own transformation, but do so while also navigating the global pandemic.

We delivered 37% growth in net revenue in fiscal ’21 versus fiscal ’20 with double-digit growth seen across all of our businesses. Our adjusted EBITDA losses have narrowed significantly compared to fiscal ’20. And we significantly reduced our cash burn as we became much more disciplined and selective in where we invest. Despite a challenging industry backdrop in Canada during Q4, Canopy increased net revenue by 38% versus a year ago, with our Canadian recreational cannabis business outperforming many of the Canadian LPs who have reported thus far.

I’m proud of all that we’ve accomplished over the past year, but we are not done. At Canopy, we’re on a mission to unleash the power of cannabis to improve lives. In order to support this mission and to capitalize on the industry’s immense growth potential for the next decade, we’ve built an organization with a strong foundation for the journey ahead of us. Our organization has been developed to put the consumer at the heart of everything we do. We leverage best-in-class insights to guide our innovation, creating authentic brands and high quality products, which will be widely distributed across all channels at the right price. This allows us to produce at the scale and efficiency, which will ultimately lead to strong margins, which then can be reinvested to drive further momentum in our business. This is what we at Canopy refer to as our flywheel effect. As our flywheel gains momentum, it leads to stronger top-line growth, improved profitability and positions us for long-term success.

And all this will be done with our commitment to build our business for good, to invest in communities to build economic opportunity and to deliver social justice reforms. We’re also stepping up our commitment to diversity, equity and inclusion, or DE&I, and recently hired a VP of DE&I. DE&I is a top priority for us and we’re taking accountability by creating equity in our talent processes and encouraging an inclusive environment for all traditionally marginalized group — groups.

Now, let me discuss the progress we’re making against our strategic priorities to become a stronger, leaner company that’s well positioned for success. We’re building momentum across all of our product lines and our recently announced acquisitions in Canada further enhance our competitive positioning and strengthen our product portfolio.

The Ace Valley acquisition adds one of Ontario’s leading premium cannabis brands with a loyal following of millennial and Gen-Z consumers. Ace Valley has a strong focus on ready-to-enjoy products including vapes, pre-rolled joints and gummies that complement Canopy’s current product portfolio. We plan to leverage our sales, distribution and production strength to expand the product portfolio and rapidly scale Ace Valley across Canada.

In addition, we announced our plan to acquire Supreme Cannabis, a top 10 license producer in Canada with a leading premium brand portfolio. This acquisition brings in Supreme’s flagship 7ACRES brand and ultra premium brand, 7ACRES Craft Collective. The acquisition also adds a low-cost scalable cultivation facility at Kincardine, Ontario. This hybrid greenhouse facility has a proven track record of consistently producing premium flower from highly sought-after strains at low cost. Furthermore, we estimate CAD30 million in synergies to be captured across cost of goods sold and SG&A. This transaction is pending regulatory approvals and Supreme shareholder vote, and is expected to close before the end of June.

Turning to some highlights for our key products and brands. In flower, we remain the market leader in the total flower category in the Canadian recreational market with Q4 market share exceeding 19% based on our internal market share tracker. Twd. has become the number one flower brand in Canada with six out of the top 10 SKUs as of Q4. We strengthened our Tweed brand with lineage-strain named products now in stores in Ontario and expanding to other region. And we also launched Vert brand in both flower and pre-rolled formats, exclusively in Quebec. During Q4, our premium flower brands combined to capture a leading 10.9% share of the premium flower segment in Canada, and we will significantly increase the share with the addition of 7ACRES once the Supreme acquisition closes. Looking forward, leveraging learnings from our flower quality initiatives, we will introduce several new products that we believe will better resonate with consumers and offer superior experiences across key attributes such as taste, aroma, effects and packaging.

In vapes, we strengthen our Canadian vape business following the transition to 0.5 ml cartridges from 0.42 mls, which is driving market share improvement. We also began shipping 1 ml cartridges to select provinces with plans to further expand our offerings in the 510 segment as well as in all-in-one vapes. Importantly, the addition of Ace Valley to our vape portfolio immediately makes Canopy the number three overall producer for vapes in Canada, and the number one for all-in-one vape pens in Q4. Looking forward, we’re focused on expanding distribution of Ace Valley brands, as well as new product launches across our vape portfolio in both Canada and the U.S.

Turning to beverages. During fiscal ’21, we launched our beverage portfolio in the Canadian rec market and captured a 35% dollar share of the total beverage category during the full fiscal year ’21. We’re continuing to expand our beverage portfolio and started shipping our new Tweed Iced Tea beverages in lemon and raspberry flavors with 5 milligrams of THC. Since launching late in Q3, our Quatreau CBD beverages have captured the number one market share among ready-to-drink CBD beverages in Canada. And during Q4, we launched Quatreau CBD beverages in the U.S., and announced the distribution agreement with Southern Glazer’s Wine & Spirit, becoming the first CBD beverage brand to sign with a national alcohol beverage distributor. Looking forward, we plan to further expand our beverage portfolio with new line extensions and flavors during the key summer selling season.

In edibles, Canopy’s first gummy in Canada, Twd. Strawberry, hit the market in late February and both distribution and velocity have been climbing each week. After two months in market, Twd. Strawberry gummies are already at 4% share of the Canadian gummies market, and that’s with just one SKU. In the U.S., Martha Stewart CBD gummies continued its success with sales continuing to grow month-over-month. Based on IRI data, Martha Stewart CBD was the number nine brand in the CBD supplement category in the entire food, drug and convenience channel for the four weeks ended April 18th. Martha Stewart CBD has also won multiple industry awards, recognizing the significant impact this brand has made in the short timeframe since it launched last fall. Martha Stewart CBD won two Digiday awards and a SABRE award. Digiday Awards recognize the companies and campaigns using modern content to modernize media and marketing. And the SABRE Awards recognize superior achievement in branding, reputation and engagement. We’re very proud to be recognized for brand excellence against established brands and products outside of the CBD space, and we look to further leverage our relationship with Martha Stewart in her new role as Canopy’s Strategic Advisor.

Turning to our other consumer brands. BioSteel’s ready-to-drink sports beverages are now hitting the store shelves in earnest, leveraging Constellation’s beer distribution network. It’s still early days, but results have been encouraging so far with the brand already the number seven sports drink brand according to IRI data, with an ACV of just 3.6% for the 13 weeks ended May 16th. Sports and athlete partnerships continue to drive brand awareness and brand credibility. BioSteel unveiled a long-term brand ambassador partnership with All-Star basketball player Luka Doncic of the Dallas Mavericks, who was also appointed as Global Chief Hydration Officer at BioSteel. And BioSteel kicked off a multi-year partnership with the U.S. Soccer Federation. Storz & Bickel celebrating its 20th year, concluded a fantastic year with a 67% year-over-year growth driven by expanded distribution in the U.S., as well as a strong consumer pull for its vaporizer products across many markets around the world. We are actively working to expand capacity to meet consumer demands. And This Works achieved strong U.S. retail growth, led by Amazon, thisworks.com, Ulta and Nordstrom despite a challenging backdrop for the brick and mortar channel due to COVID.

With our businesses on a solid footing, we are now accelerating our innovation agenda to drive top-line growth and profitability. Our investments in insights and innovation are enabling us to fill a new product pipeline focused on premiumization and enhance 2.0 product offerings, as well as consumer tested mood management products that target specific consumer need states including formulas to help consumers connect, focus, manage stress, unwind and sleep.

Turning now to our U.S. strategy, we remain focused on advancing our U.S. ecosystem and expect significant cannabis reform to take place during this Congress. We’ve seen substantial bipartisan momentum over the last couple of months. SAFE Banking passed the House for the third time with significant support from both sides of the aisle. Two Republican members of the House, Dave Joyce and Don Young, introduced a full de-scheduling package in recent weeks. And just last Friday, the MORE Act was reintroduced in the House of Representatives by Chairman Adler, a comprehensive de-scheduling bill that would legalize adult use cannabis and allow for interstate commerce. The bill also includes social equity provisions to help undo the harms caused by cannabis prohibition and begin repairing the communities that have been disproportionately harmed by the war on drugs.

There’s also an incredible amount of public support for federal legalization. The United States Cannabis Council, or USCC, just released some polling information from some fairly conservative states, meaning Arizona, Utah and West Virginia, which highlighted that there is overwhelming support for federal legalization, in fact, 70% of respondents in all three states support federal legalization. All eyes remain on the Senate as we expect Booker, Wyden and Schumer’s cannabis legalization bill to be introduced in the coming weeks and a potential vote before the end of the year. And at a state level, I’m also very pleased to see New York State recently passing adult use legalization, and we expect additional states to pursue legalization.

Against that backdrop, we continue to lay the foundation and explore ways to further capitalize on the U.S. opportunity. Specifically, we’re encouraged by the performance of both Acreage and TerrAscend. Acreage reported positive adjusted EBITDA for the first time in its history in the most recent quarter. Additionally, revenue growth reaccelerated to 50% growth year-over-year, also validating Acreage’s refocused strategy. Acreage is well positioned to grow in key states such as New Jersey, New York and Pennsylvania. TerrAscend has been accelerating its growth strategy while delivering top tier margins. A combination of recent acquisitions in Pennsylvania and Maryland, as well as a ramping of its existing operations should position TerrAscend well for further growth. Acreage also has access to all of Canopy brand IP — all of Canopy’s brands and IP through our arrangement. Acreage already sells Tweed-branded flower products in their dispensaries and is expected to launch THC-infused beverages later this year. And our recently announced distribution partnership for our CBD and CPG brands position us strongly in building out route to market infrastructure.

Finally, we are executing on our path to profitability, while still investing for growth. We’re on track to deliver CAD150 million to CAD200 million of cost savings across our COGS and SG&A, and we remain committed to delivering positive adjusted EBITDA by the end of our fiscal ’22. In summary, I’m proud of the performance delivered by the Canopy team during a dynamic and volatile year, and pleased with the transformation we’ve made to position us for long-term success.

With that, I’ll turn it over to Mike for a review of financial results in more detail.

Mike Lee — Executive Vice President and Chief Financial Officer

All right. Thank you, David, and good morning, everyone.

With Q4 complete, we are wrapping a year of business transformation during a volatile macro backdrop and an increasingly competitive market. During this past fiscal, we made tremendous progress in both our commercial and supply chain execution, while also improving product quality. Our results are moving in the right direction and we are confident that we can further scale our business on a path to profitability in fiscal ’22. So with this, let me jump into our results.

In fiscal ’21, we generated net revenue of CAD547 million, representing a year-over-year increase of 37%, with strong double-digit growth across all of our businesses; our reported gross margin in the fiscal was 12%, and our adjusted gross margin excluding restructuring charges incurred during the year was 17%; our adjusted EBITDA loss during the fiscal was CAD340 million, an improvement of 24% versus prior year; and free cash flow in fiscal year narrowed to an outflow of CAD630 million, primarily driven by a 77% reduction in capex and a 24% improvement in our adjusted EBITDA.

Now let me briefly summarize the fourth quarter. Revenue grew 38% year-over-year to CAD148 million; our reported gross margin in Q4 was 7%, and our adjusted gross margin was 14%; our adjusted EBITDA loss in Q4 narrowed to CAD94 million; and our free cash flow in Q4 narrowed to an outflow of CAD124 million.

Now, before delving further into Q4 results, I would like to highlight a change that we made to our segment reporting, which became effective this quarter. Prior to Q4, we had two operating segments, which were also our reportable segments as follows. We had cannabis, hemp and other consumer products, and we have RIV Capital. Following the RIV Capital divestiture in February, we are now reporting our financial results for the following two reportable segments: Global Cannabis and Other Consumer Products. Our Global Cannabis segment includes our Canadian cannabis operations for both recreation and medical, as well as our international medical and other cannabis businesses, including our U.S. hemp-derived CBD business. Our Other Consumer Products segment includes Storz & Bickel, This Works, BioSteel and other ancillary revenue.

Now let’s dive further into Q4, starting with the Global Cannabis segment, which grew 27% year-over-year to CAD101 million. Our Canadian rec business grew 39% to CAD61 million, driven by 40% growth in our B2B channel and 37% growth in our B2C channel. Our Canadian medical business grew 1% to CAD14 million. Our international medical and other cannabis business grew 20% to CAD27 million, driven by growth in our U.S. CBD business partially offset by sales declines in Germany as a result of ongoing COVID restrictions.

Moving further into Canada, our B2B revenue growth was driven by several factors, including store openings, particularly in Ontario, as well as volume growth from our value flower products and contribution from our 2.0 products, which delivered 5% of gross B2B revenue in Q4. This growth was partially offset by a negative mix shift toward the value flower category, including newer lower price points, as well as a shift to larger pack sizes.

And to further illustrate what’s happening in our Canadian flower category, it’s best to examine Q4 results relative to Q3 to further understand the volume, mix and price impacts. Starting with volume, we saw a 23% increase in overall flower volume, driven primarily by 28 gram packages in the value segment and partially offset by declines in the 1 gram, 3.5 gram and 5 gram packages. Moving on to mix, we saw a negative product mix impact of 9% due to a shift into large pack sizes during the quarter, as well as a further shift into the value price segment. On price, we saw a 5% negative price impact in part due to the provincial mix of sales across the provinces as we had a greater percentage of volume from Alberta and Ontario, which have lower average prices compared to other provinces.

So in summary, our Canadian rec flower sales grew 9% from Q3 to Q4, led by volume growth of 23%, negative product mix of 9% and a negative price geo mix of around 5%. Our rec B2C cannabis sales in Q4 increased 37% versus the prior year due to an increase in store count, up from 22 stores last year to 33 this year, as well as a 5% increase in same-store sales.

Let me now wrap up our cannabis top line discussion with a recap of market share in Canada using our internal share tracker. Our overall market share showed a slight decline of 20 basis points to 14.8% in Q4, where we gained share in Ontario and lost share in BC and Alberta. Our flower share increased by 60 basis points to 19%, and we maintain the number one share position in total flower, as well as the number one share position in both premium and value flower. We captured a number two share in beverages, with a 29.9% share, and we captured a number two share in edible extracts with a 22% share.

Moving onto our Other Consumer Products segment, which grew 66% versus prior year to CAD47 million in net revenue. Storz & Bickel grew 52% year-over-year, benefiting from the more effective distribution in the U.S. and the strong consumer pull, notably for the Volcano Hybrid, the Mighty and Crafty Plus Vaporizer. This Works grew 2% year-over-year due to continued strong e-commerce sales and sales of the Stress Check hand sanitizer, which was launched in the UK and the U.S. during this past fiscal. BioSteel experienced strong year-over-year growth in part due to distributor load-ins for our ready-to-drink beverages in the U.S.

Let’s now move on to an analysis of gross margin for the quarter. Reported gross margin in Q4 was 7% and adjusted gross margin, excluding CAD10 million of restructuring charges, was 14%. Adjusted gross margin in Q4 was negatively impacted by lower production during the quarter as a result of the ongoing COVID restrictions, unfavorable product mix, as covered in my remarks a few moments ago, as well as inventory charges due in part to the write-down of certain packaging inventory ahead of a packaged change that is planned for many of our flower SKUs. And we decided to modify our packaging on our flower products based on consumer insights coming out of our flower quality initiatives. And This Works show that consumers prefer bags as a more approachable packaging that’s easy to open, that’s resealable, retains moisture better and retains aroma better, creating a better experience for the overall consumer. Adjusted gross margin in Q4 benefited from payroll subsidies of approximately CAD4.5 million received from the Canadian government pursuant to a COVID-19 relief program. If you exclude both the inventory charges and the payroll subsidy benefit, gross margins would have been approximately 24% during the quarter. The remaining shortfall to our expected gross margins for Q4 was driven by the negative flower mix that I discussed a few minutes ago.

Next, I would like to cover our operating expenses. Overall SG&A in the fourth quarter decreased 25% versus the prior year. We had an 11% reduction in sales and marketing expense, a 35% decline in G&A expense, and a 23% reduction in R&D expense. Stock based compensation decreased by 76% year-over-year. Our net loss during the quarter was CAD617 million, inclusive of other expenses of CAD367 million, most of which is tied to non-cash fair value adjustments related to our various financial instruments, driven mainly by the rise in Canopy share price during the quarter. Our net loss also included CAD85 million of asset impairments and restructuring charges.

Now, turning to free cash flow. Our free cash flow during the quarter of fiscal ’21 was an outflow of CAD124 million, which represents an improvement of 59% versus the prior year. Inventory decreased by 6% year-over-year to CAD368 million. And capex declined to CAD27 million, down from CAD94 million in Q4 of last year.

Next, I would like to briefly speak to the progress against our cost savings program and our path to profitability targets, which we announced during our last earnings call. Our Canada site rationalization program that we announced in December is well underway, and these sites have ceased production and our burn rate has largely been eliminated except for certain carrying costs that we will continue to incur until these assets are divested. Our ops team reorganized and this reorganization was completed during Q4, resulting in a leaner more integrated global ops team. We announced the closure of our Denmark facility, which is currently underway. And we completed the divestiture of RIV Capital in February. And these initiatives generated approximately CAD7 million of cost savings in the quarter, as the savings began to flow through towards the latter part of the quarter.

But it’s important to note that these underlying actions, as well as the additional initiatives taken thus far have put in motion over CAD100 million of savings that will begin to phase in during the next several quarters. For one, the site rationalization program will deliver savings of nearly CAD40 million in FY ’22, in turn reducing our cultivation surplus and bringing supply and demand into balance. The implementation of our operations org redesign will reduce our cost of goods sold by CAD10 million. Our initiative to specialize cultivars by site is phasing in, and this will generate CAD10 million of savings through increased productivity. And as you know, we’ve completely overhauled our SG&A structure, leading to new efficiencies that will deliver CAD45 million of SG&A savings during this upcoming fiscal year. We remain committed to our path to profitability as we continue to invest in things such as consumer insights, research and development, and business development activities in the U.S., and we are focused on driving our top line while meeting our COGS and SG&A targets in fiscal ’22.

Before I close, I would like to offer a few key factors to consider as it relates to the outlook for Q1. First, we expect our Canadian rec business to face continued headwinds from COVID, both from reduced traffic and tighter inventory management at the provincial boards. Our international medical business is also facing COVID headwinds, but an improved supply situation plus lifting of lockdown measures in Germany should drive stronger growth in the coming quarters. Our consumer products business, we expect S&B to continue its solid growth trajectory, driven by strong demand. Sales at BioSteel, which benefited from some of the load-in during Q4, could see more modest growth in Q1 as distributor sell through their inventory prior to reordering. Lastly, we expect our gross margins to improve in coming quarters as the cost savings ramp, but there could continue to be some volatility in the near term.

In conclusion, despite near-term headwinds, our businesses are showing renewed momentum and we’re excited against the opportunities that we have in front of us, namely with the cost savings program, as well as the investments we’re making for the long term, and we believe we’re on a sustainable growth trajectory to achieve profitability before the end of this fiscal year.

This now concludes my prepared comments. Operator, David and I would be happy to take questions from the analysts.

Questions and Answers:

Operator

[Operator Instructions] Your first question comes from the line of Heather Balsky with Bank of America. Your line is open.

Heather Balsky — Bank of America Securities — Analyst

Hi. Good morning. Thank you for taking my question. You reaffirmed your guidance for positive EBITDA in the back half of fiscal ’22. And it would be great if you could just help bridge us from where you are currently to what gets you to positive levels. And just kind of thoughts about what sales need to do, what mix looks like and all that? Thank you.

Mike Lee — Executive Vice President and Chief Financial Officer

Yeah. Thanks, Heather. I’ll take first shot at it, and then David could build. It all starts with growth. And as we mentioned in our remarks that each of our businesses posted double-digit growth in this past fiscal, and we’re really happy with the momentum that we’re seeing across each of our businesses. And in Q3, we did provide medium-term guidance around growing 40% to 50% a year for the next few years, and our expectations are — in FY ’22 are consistent with that. Additionally, we have the benefits of Ace Valley and Supreme, which will further provide tailwind in achieving our profit goals. But it does start with growth and this really is going to be the year of growth across both Canada and the U.S.

In Canada, our projections on market growth are really tied back to store count, projecting that stores are going to grow another 50% roughly to 2,400 stores by year end, and we’ve been quite impressed with the progress that we’ve been seeing recently on store count. And in the U.S., our growth projections are really tied to all the brand launches that we’ve announced of recent. So, we’re getting real traction with Martha Stewart CBD gummies. We’re getting traction with Quatreau, which is in early days, but with our Southern Wine & Spirits agreement, we’re really confident that we’re going to scale quickly. And then we’ve got BioSteel, which is leveraging the beer network to really drive distribution in the U.S. So, we are counting on growth for our path to profitability.

When you get to the underlying metrics in the P&L, there is no question about it that we are going through a business transformation in operations and supply chain. And we conducted a very thorough review of our operations and supply chain last fall, and we now have a roadmap that we’re executing against. And as we sit here on June 1st, we’re on track with that roadmap, and the cost savings that we projected on balance are coming through, and now it’s just a matter of executing.

The SG&A is also a critical piece of our cost savings program. We just exited our annual planning cycle in the wake of massive restructuring across the entire business, and now we have the entire organization program against new operating budgets across the Company, and we simply need to adhere to those budgets and headcount plans, which we’re confident that we will do because we’ve built the org to really scale the right way. So, look, a lot of of work underway, a lot of the work is behind us, it’s just a matter of it phasing through the P&L quarter-by-quarter over the next several quarters.

David…

David Klein — Chief Executive Officer

Heather, yeah, the only thing that I would add is that we’re doing all of that while we’ve continued to maintain the discipline to invest in insights, innovation and brand building in the U.S. and Canada, and make investments in preparation for entering the U.S. THC market. But we think that we can do — we can make those investments and still have a very high degree of confidence in being able to turn a profit by the end of the fiscal year.

Operator

Your next question comes from the line of Adam Buckman with Scotiabank. Your line is open.

Adam Buckman — Scotiabank — Analyst

Hey, good morning, and thanks for taking my questions. So, bit of a follow-up on the storefront commentary before. There has been some commentary in the market about saturation of stores in specific markets. I was just wondering how your internal model incorporates the potential for diminishing returns as new stores are added, or whether that’s an issue in your view.

Mike Lee — Executive Vice President and Chief Financial Officer

Yeah. I think it’s a market-by-market view at this point, Adam. And Ontario is still early days in its maturity. And although we’re seeing pockets of, call it, diminishing returns on certain — on stores in certain locations, broadly speaking, it’s still early days. And we expect Canada grow to several thousand stores over the next five to 10 years, so it’s early days. I’d say the most saturation we’re seeing is in Alberta, and even that is pretty modest at this point. So, not top of mind concern at this point, Adam. It’s still a very robust market. The illicit market continues to convert. I think we hit that 50-50 milestone last fall. And more and more consumers are coming in. I think 2.0 products helped to drive that interest in the category. And accessibility continues to be the number one growth opportunity in Canada.

David Klein — Chief Executive Officer

And I think the retailers are maturing their business models as we move along. You see in our retail channel, we have the 5% same store sales growth, that Mike called out. We’re seeing retailers get more sophisticated in terms of product assortment and making their storefronts more attractive to people who currently purchase in the illicit market, and actually new entrants to the space. So, I think, we’re — as an industry, we’re counting on a lot of store openings, in particular, in Ontario to get over that 1000-store hurdle, but I believe that the retail market will remain fairly robust for the foreseeable future.

Operator

Your next question comes from the line of Vivien Azer with Cowen. Your line is open.

Vivien Azer — Cowen and Company — Analyst

Hi. Thank you. Good morning. David and Mike, just to follow up on the point that you just made, both on the need for growth to really drive the operating leverage and help you achieve your targets for profitability, can you provide an update on what you’re seeing in terms of the cadence of Ontario growth and how we should think about that in terms of flowing it through to the model? Because given that the adjusted EBITDA loss expanded sequentially in the quarter, it’s hard to understand really kind of from a quarter-to-quarter basis when the business should really start to inflect.

And then if I can just squeeze in a housekeeping item, Mike, you broke up when you were offering the SG&A savings for FY ’22. So if you could repeat that, that would be helpful. Thank you.

David Klein — Chief Executive Officer

Okay. So, I think it’s a couple of things. And so, first of all, when — our expected growth in Canada would probably be in line with the current year’s growth, right. So, we’re not expecting outsized growth in Canada, again [Phonetic] most of that is the opening of additional stores, which pulls over more people from the illicit market. Also, Vivien, I think is when you’re looking at our total business, I think you need to take into account the growth of our consumer brands, our consumer businesses, as they start to accelerate penetration in the U.S. market.

And, Mike, I’ll let you talk about the SG&A.

Mike Lee — Executive Vice President and Chief Financial Officer

Yeah. So, Vivien, I don’t know where I broke up, but my remarks were really around the org work that we’ve done over the past fiscal year, and we just exited our annual planning cycle whereby we have built in CAD45 million of savings year-over-year. My point is the work is done, the orgs are in place, we simply need to execute against these budgets.

Operator

Your next question comes from the line of Graeme Kreindler with Eight Capital. Your line is open.

Graeme Kreindler — Eight Capital — Analyst

Hi. Good morning, and thank you very much for taking my question. I wanted to follow up on an item that was listed in the press release about the grams sold in the quarter exceeding grams harvested by 40%. Putting that into context with all the restructuring that’s been done at the various levels at cultivation and then bringing in some other acquisitions here from Canopy, I’m curious when you think about these medium to long-term targets on growth, does the Company expect that it’s going to be in a net buyer position on biomass? You talked about rightsizing supply versus demand. I’m just wondering what that looks like over the medium to long term here in terms of sourcing reliable product, putting that through down to the product level, and what that might do on the cost structure. Thank you very much.

David Klein — Chief Executive Officer

Yeah. So, I’ll start, Graeme. So, first of all, the model that we’re shooting for does assume that we’re net buyers in the market. We think there are — there is a component of your portfolio that you want to control and own production for and that’s at the higher end of the spectrum. And then we want the ability to flex our business by buying from third parties. We think it’s a much more efficient capital — a way to — a much more efficient way to deploy capital. And we think that at least for the foreseeable future, it will also be a cost-effective approach to meeting the consumer demand. So that — we’re here by design. And then I guess one tangential point, super excited around the production capability that we get out of Kincardine, because of its premium nature of the output that’s come out of that facility over the last couple of years. So we think that’s exactly a good example of what we’re trying to get to. We want to be able to produce the premium products, and then we want to have flexibility to go to the market for everything else.

Operator

Your next question comes from the line of Rupesh Parikh with Oppenheimer. Your line is open.

Rupesh Parikh — Oppenheimer & Co. — Analyst

Good morning. Thanks for taking my question. So I just wanted to discuss to some of the consolidation that we’ve seen in the space recently. So I’m curious to how you guys feel about your competitive positioning versus some of the new proposed combinations out there? And going forward, is M&A still a focus within Canada?

David Klein — Chief Executive Officer

Yeah. So, first of all, I’ll make the statement that consolidation in most categories and certainly in our categories is generally good for the market and the consumer and the players in the market. Everyone, of course, has to respond to the M&A activity that takes place around them, but, in general, we’re pretty positive about the activity in the marketplace. We’re very pleased with the premium positioning we got from Ace Valley and we hope to get from Supreme as we come to the place where we can close that transaction. So, we’re very happy with our portfolio in Canada and with the ability of that portfolio to travel to the U.S. So then if you look at where we would focus next with our balance sheet and with an eye toward M&A, it’s going to be the U.S. Again we think we’re positioned in the way we want to be positioned in Canada. So — yeah, I wouldn’t see us doing much more in the way of M&A in Canada.

Operator

Your next question comes from the line of Michael Lavery with Piper Sandler. Your line is open.

Michael Lavery — Piper Sandler — Analyst

Good morning. Thank you. Just was curious if you could give some thoughts on beverages. And I guess since you report them together maybe the whole sort of 2.0 bundle, how does that match with some of your expectations? Is the scale adequate for every piece of those? And what’s your outlook for how that evolves going forward? Does beverages, for example, really need on-premise or higher THC limits to really get going? Or — just how do you think about — how should we be thinking about the outlook for that segment?

David Klein — Chief Executive Officer

Yeah. Michael, so good question. We spent some time retrenching a little bit around innovation in drinks to get the proposition right for consumers. We see brands like our Deep Space doing really well at 10 milligrams, which in some ways makes sense in the Canadian market which constricts the number of literally units that a consumer can purchase. And so you’re in many regards better purchasing 10 milligrams in a unit than purchasing 2 or 2.5 milligrams, which were some of our offering. Now, I still think there is a real reason for being at each THC level that’s in our portfolio, but I think we need to — before the real power of that unlocks in the Canadian market, we need to get past the equivalency standards that are restricting what consumers can take away. And we expect that that will happen, and we’re going to be prepared for that when it happens, but that’s the big unlock in my mind from a beverage standpoint in Canada.

Mike Lee — Executive Vice President and Chief Financial Officer

And I think you’re going to see accelerated NPD in Canada over the next fiscal year. We just launched Tweed Iced Tea. We had a line extension on Houseplant with its lime flavor. And I’m really proud of the work that we’re doing within our NPD team and our R&D team to really scale up our internal capacity to get more drinks out into the market. And as David mentioned, there’s going to be more variety at more THC levels that we think will match consumer needs in the market.

With respect to the U.S., we’re on the wake of a new launch of Quatreau CBD that we’re extremely excited about. And the arrangement that we have with Southern Wines & Spirits is really going to position us well to scale this brand better than any other in the market. And at this point, it’s just really about building distribution, supporting the rollout with local marketing activation and really leveraging this ecosystem that we’ve built in the U.S.

David Klein — Chief Executive Officer

Yeah. And I’m going to use Quatreau, Mike, as a jump off to talk about what we mean when we talk about this CPG approach to our portfolio, right. If you look at Quatreau, it’s a drink that our insights team identified early on is meeting a consumer need state for relaxation and calm and more focus, right. And so we set out to produce a product that was very effective in terms of its CBD delivery and its effect on the consumer that would consume the product. We also wanted to make sure that we got the taste profile right. We then launched it in Canada, and we’re able to quickly grow market share in Canada, ending up at the end of the year the number one CBD beverage in Canada. We then brought that brand to the U.S., and started selling it through our direct-to-consumer channels. And then ultimately because of our partnership with Constellation, really tapped into their alcohol distribution network and creating that distribution platform at Southern Glazer’s Wine & Spirits.

So, I think that — that’s a picture of what we’re trying to do across our entire portfolio; use insights, innovative outstanding products, launch great brands. And by the way, we’ve won — we’re in the running for design awards on Quatreau. When we launched it, we had — we reached about — or we reached north of a billion kind of hits on the Quatreau brand, right So, it’s that kind of ecosystem that we’re talking about when we say we want to bring the CPG mindset across cannabis. I think Quatreau is a great example of that. And now we have to see how it performs in the market, but we’re growing distribution rapidly in the state Southern is in, and I think we’ll start to see results over the next couple of quarters.

Operator

Your next question comes from Aaron Grey with Alliance Global. Your line is open.

Aaron Grey — Alliance Global Partners — Analyst

Hi. Good morning, and thanks for the question. So, I just wanted to dive in a little bit on gross margin, right. So, 24% if we exclude some of the inventory charges and payroll subsidies benefit. Last call you had talked about of 40% for the full year — fiscal year ’22, early on the call today you talked about improvements come in the quarter but still some volatility near term. So, would just love to get your perspective in terms of the outlook for the full year, potentially on the 40% and how important that is to kind of reach your target to profitability by the back half of the year? Thank you.

Mike Lee — Executive Vice President and Chief Financial Officer

Yeah. Thanks, Aaron. Look, the 40% margin goal is important over the long haul, but it is not critical to our path to profitability commitments that we’ve made. The work that we did over the fall on the operations and supply chain really are the pillar to our pathway to profitability. And as I mentioned earlier that work is on track.

When I think about the near term on gross margin, the volatility that I referenced earlier is really a function of two things. Number one, it’s when you think about the COVID impacts on our business in Canada, we have a high fixed=cost operating environment that is very sensitive to volume fluctuation. So even though I’m quite proud of the results that we posted in Q4 on revenue, it did translate into lower-than-expected production, which ends up creating a bit of a deleverage impact. And that impact we expect to see continuing into the next quarter or two. So it’s the leveraging/deleveraging impact that we’re facing. That’s the biggest challenge.

I’d say the secondary challenge that we’re facing is just thinking about price and mix in the Canadian market. And for everyone that’s watching market share data, you can see that Canopy has established nearly a 30% market share in value flower, which we’re very happy about, because going to my earlier remarks, volume matters in our facility and it does create economies of scale, but at the same time we need to premiumize our business. And when you think about the discussion we just had about beverages and gummies that David talked about earlier, the benefits of Supreme and Ace Valley will further premiumize our business, and that premiumization is really going to pave the pathway to get into that 40%. So, 40% still a goal. We’re still very focused on it. We want to be above that over the long haul, but it’s not critical to our immediate path to profitability targets.

Operator

Your next question comes from the line of Glenn Mattson with Ladenburg Thalmann. Your line is open.

Glenn Mattson — Ladenburg Thalmann & Co. — Analyst

Hi, thanks for taking the question. David, you — unfortunately in this environment, all CEOs have become kind of political pundits to one degree or another, and various management teams have offered up [Phonetic] their view over the last couple of weeks in the earnings season on path to the regulatory change in the U.S. Just a little more color on kind of the comments you made. It sounded a slightly more less optimistic than some of the other management team. Just you talked about maybe hopefully a bill — Schumer bill would get voted on perhaps this year, that — just the tone of that, what you’re looking for? What your kind of best case scenario is over the medium term on that front? And I guess maybe thoughts on what you would view as the ideal outcome perhaps this year? Just some comments around that would be good.

David Klein — Chief Executive Officer

Yeah. So look, whatever any of us say as it relates to the political environment, we’re going to be wrong. But I’m really bullish and have been for a while in terms of the speed that I think things are going to move. I believe we’re in a position now where you have Republicans and Democrats who are — each trying to craft their own bills, what they’re not questioning is should cannabis to be legalized, they’re simply questioning the how, right. And so that’s where the negotiation will take place. I think that it’s going to move — I personally believe it will move faster than maybe a lot of people think, because when you get that many people aligned on the what, sometimes the how kind of gets negotiated. And so I expect to see that happening. The next big move will be to see what senators Booker, Wyden and Schumer come out within in their bill to understand how passable their bill is in and of itself.

And look, I think the right answer over time is we want full up permissibility across the U.S. with a regulatory environment that properly ensures the right amount of quality and so forth. From a consumer standpoint, we want to make sure that the regulatory environment supports all of the things that we’re passionate about like avoiding under age use and so forth, right. So we want to get — we want to see a proper regulatory bill and we want to see full up interstate commerce, so that this business can function just like every other business in the United States. And again, I’m pretty bullish we’re going to see all of that in the not-too-distant future.

Operator

Your next question comes from the line of John Chu with Desjardins Capital. Your line is open.

John Chu — Desjardins Capital — Analyst

Hi. Good morning. I just wanted to focus on the concept you’re talking about just recently to premiumize the business. So it sounds like it’s a bit of a tough balance here. You need the volume to drive the high fixed-cost nature of the business, but you also need a premiumness [Phonetic] of that to drive the margins higher on the other front. You’re buying cheaper biomass, but you also want to control the premium biomass. So, I’m just understand that balance there. And is there a chance that maybe you decide to shutter some more capacity one that’s focused more on the value biomass to then help be less reliant on new net volume?

David Klein — Chief Executive Officer

Yeah. So, good question, and I think this strikes to some of the volatility that Mike talked about in his comments, right. Because as you all know, this is an agricultural business, and it takes a while to change your profile of what you’re growing in your facilities, and then it takes a while even for that to flow its way through your inventory into finished goods that ultimately show up on your P&L. So, we are absolutely undergoing as part of our transformation that change that you described, John, to drive toward more and more premium offerings, and we do think that were helped by Supreme and Ace Valley.

But I also want to play out the premiumization that’s been going on in our own portfolio across the price points even where we brought quality up on all of our brands from a consumer standpoint. We’ve — we have an initiative in the premium segment around DOJA, that’s really being well received by the provincial boards and by our consumers. And so premiumization — and look, I kind of believe our industry will look a lot like some other CPG categories where you’ll have a very robust value segment and a very robust premium segment, and then there is a lot of business to be had in the middle, but you want to make sure that you’re winning in one or both of the other two segments. So, we are proud of the fact that we’re number one in value and number one in premium. We have a lot to do, but we think we’re on the right path. And then we think that gives us the right production environment to get to the kinds of margins we want. It just takes a while to transition into that.

Operator

Your next question comes from the line of Pablo Zuanic with Cantor Fitzgerald. Your line is open.

Pablo Zuanic — Cantor Fitzgerald — Analyst

Thank you. David, just following up on the political questions. Do you have any views or insights in terms of the role of the Biden White House instead of Schumer’s bill? Because they are still — the Biden White House seems to be against Washington, DC, having rec sales, there has been previous commentary on staff questions there about policies on cannabis. So just any thoughts on that? Because if it’s in isolation, there is almost no input from the Biden White House. I don’t really see where that bill really goes.

And then related to that, if I may, how are you thinking about your contingent deals in the U.S.? I mean, Acreage and TerrAscend overlap in New Jersey and Pennsylvania, so that could be an issue when you have your triggering event. I mean, does it mean that you have to think about other contingent deals in the near or medium term? Thank you.

David Klein — Chief Executive Officer

Yeah. So, I’ll take that almost in three parts, Pablo. So, as it relates to the Biden administration, again, anything can happen in the political world. But I don’t believe that the Biden administration intends to stand in the way of the will of the people, which as I mentioned, there seems to be a lot of support across the political spectrum for legalization in cannabis. And I think if Congress can come forward with legislation that gets enough votes to make it to the Biden — President Biden’s desk, I suspect that he won’t stand in the way of it. And again, it’s just my view.

In terms of overlap, we actually quite like the fact that we — if you divide up the United States, there are — there is that big population corridor that is Pennsylvania, New York and New Jersey. Both TerrAscend and Acreage are well positioned there. I think the market is still fragmented enough that we’re not going to have any obvious competition issues on day one, but we’ll keep watching that. I think you then look at the rest of the U.S. and you say, there are other population areas that we — that we’re not strong in today. But I think you’ll see Acreage and TerrAscend at least considering how to address those over a period of time.

And as it relates to would we look on — would we look at additional contingent deals, I’ll just come back to the statement I made earlier, I think we’ve built out the footprint that we’re very happy with in Canada. We’re going to continue to use some of the CAD2.5 billion of cash we have on our balance sheet to drive innovation and create the consumer connected brands that we want to create. But once we do that, the rest of our capital will be focused on the United States. And so we’re going to watch very carefully how things unfold and what are the events that allow us to come into the U.S., which — again when you look at the different forms of legislation, the wording will be really important, because there are several paths to the U.S., and it’s all going to depend upon the actual legislation as it comes forward.

Operator

This concludes the Q&A portion of today’s call. I will now turn it back to Mr. Klein for final remarks.

David Klein — Chief Executive Officer

So, thanks again for joining us today. As we enter the summer season with businesses beginning to open up across our core markets, I’m personally excited about the prospect of reconnecting in person with co-workers, family and friends. And so, as you begin your personal return to normal, I encourage you to try our products, wherever you may be, whether it’s our refreshing Quatreau beverages in either Canada or the U.S., or if it’s Tweed Iced Tea in Canada or our delicious Twd. gummies or Martha gummies or our newest addition Ace Valley pre-rolls and vapes, really encourage you to play around in the category. As investors in this category, it’s a — it’s an amazing place to be and it’s an amazing industry to be in, and I’d really encourage you to try some of our products, because I think you’ll then agree that we’re doing some outstanding things as it relates to delivering on the consumer experience.

And so with that, our Investor Relations team will be available to answer additional questions throughout the day. So have a great day everyone.

Operator

This concludes Canopy Growth’s Fourth Quarter and Fiscal Year 2021 Financial Results Conference Call. A replay of this conference call will be available until August 30, 2021, and can be accessed following the instructions provided in the Company’s press release issued earlier today.

[Operator Closing Remarks]

Disclaimer

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2021, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top